Investment Thesis
A promising set of initial trial data and a rich portfolio of drugs has not stoked investor interest yet for Moderna, Inc. (MRNA). Since its IPO in December 2018, the stock has underperformed with a gain of only ~4% compared to the ~9% rise of the NASDAQ Biotechnology Index. The shrinking revenue, lack of late-stage clinical trials in addition to the complex mechanism of therapeutics based on messenger RNA (mRNA) might have held back the investors.
The company is seeking collaborations that could boost revenue and slash expenses in the future. The rich drug portfolio backed by the positive trial data strengthens its bargaining power for lucrative deals. Meanwhile, the liquidity level remains steady to fund the future clinical development. Yet, the company trades at a sharp discount to its peers based on the price to forward sales multiple for 2019 and 2020, an opportunity to 'Buy', given the near-term catalysts and expected collaborations. Further streamlining of drug portfolio meanwhile could refocus Moderna's research efforts and sustain the premium valuation.
Source: Yahoo Finance
Moderna, a clinical-stage biotechnology company based in Cambridge, Massachusetts, with a portfolio of 21 drug candidates targeting 20 conditions currently has 13 clinical trials in progress. The mRNA, the basis of its therapeutic agents originates from cellular DNA (transcription) under normal physiological functions. The proteins are the 'workhorse' of every cell and mRNA codes for their amino acid sequence during the protein synthesis (translation), thus playing a vital role in cellular functions.
Despite the challenges in mRNA-based medicine, Moderna's pre-clinical studies have successfully demonstrated its efficacy as a therapeutic agent. The LNP (liquid nanoparticles) technology with targeted delivery of the mRNA has ensured maximum potency of the drug without enzymatic degradation and serious adverse reactions. The recent expansion of the laboratory space in Norwood, MA, could further scale-up research to boost the in-house manufacturing started last year. The company's web-based drug design studio integrated into a modular synthesis system can handle up to 1,000 orders of unique mRNA sequences per month within a turnaround time of a few weeks.
Moderna's pool of development candidates looks solid, with a few candidates standing out from the rest with positive data from phase 1 trials. The mRNA-4157, the PCV vaccine (personalized cancer vaccine) developed in partnership with Merck & Co., Inc. (MRK), has a 50-50 profit-sharing deal in the event of commercialization. It encodes up to 34 neoantigens, the unique protein sequences produced by a growing tumor. With even a single antigen eliciting an immune response strong enough to destroy cancer cells, the company believes, the multiple neoantigens encoded by the drug could result in a better prognosis for cancer patients. The company has dosed the first patient with mRNA-4157 in a phase 2 trial against high-risk resected melanoma.
Source: Company Earnings Call Presentation Q3 2019
The RSV (Respiratory syncytial virus) vaccine (mRNA-1777 and mRNA-1172) currently in a phase 1 study could potentially uncover a market opportunity worth billions of dollars. A collaboration with Merck, the company is in line for milestone payments worth $300M from the research partner as the phase 1 data readout approaches. AZD8601 targets ischemic heart failure where there is inadequate blood supply for heart muscle contraction. Currently, undergoing a phase 2 trial, the concept is to promote cardiac tissue revascularization through the targeted delivery of AZD8601 to heart tissue, thereby increasing the local concentration of vascular endothelial growth factor A. No current therapies currently focus on the heart tissue regeneration specifically. The company is waiting for the phase 2 data readout in addition to milestone payments and royalties from its research partner AstraZeneca PLC (AZN).
Source: Company Earnings Call Presentation Q3 2019
Additionally, DARPA (Defense Advanced Research Projects Agency) funds the research into mRNA 1944 for developing immunity against Chikungunya infection through antibodies. Another multi-billion-dollar market opportunity with sole commercial rights awaits Moderna as the company single-handedly develops mRNA-1647 as a vaccine against CMV (Cytomegalovirus). A phase 2 study is scheduled to start in the near term while preparatory work for the pivotal phase 3 trial has already begun. CMV is the commonest cause of birth defects in the U.S. with no vaccination currently available against the infection.
Source: Company Earnings Call Presentation Q3 2019
Moderna's topline, made up of revenue from collaborations and grants is, however, on a decline currently. The contribution from collaborations has dropped to ~78% as of the third quarter of 2019 (Q3 2019), with the Merck collaboration making up ~68%. Comprising ~51% of the total grants in Q3 2019, the Bill & Melinda Gates Foundation funds the majority of grants, as it supports the initial clinical research into a potential mRNA medicine to prevent HIV (human immunodeficiency virus) infections. The revenue generated from collaborations, which made up ~91% of the total revenue in 2018, has dropped ~61% YoY (year-over-year) in the LTM (last twelve-month) period. The company blames its lukewarm approach to forge partnerships in the wake of the 2018 IPO, the then-biggest biotech IPO ever. In contrast to ~90% YoY (year-over-year) growth in 2017, Moderna's LTM revenue, as a result, has tumbled ~57% YoY, steeper than the ~34% YoY decline in 2018. Having adjusted for the revenue recognition standard ASC-606, adopted at the start of 2019, the LTM revenue has only contracted ~35% YoY, approximately in line with the 2018 decline.
Source: koyfin.com
The impending milestone payments and royalties from Merck and AstraZeneca for RSV vaccine and AZD8601, respectively, could reverse the decline in 2020. Out of the 10 drug candidates with positive phase 1 data, the company currently owns sole commercial rights for more than half of them, providing ample opportunities for future collaborations. As declared in the Q3 2019 earnings call, the company has recently revived the efforts to strike partnerships, and if successful, could further boost 2020 revenue. Even the solo development of certain candidates such as CMV and hMPV-PIV3 (mRNA1653) vaccines looks attractive in the long run, given the sizable market opportunity which the company estimates to be worth billions of dollars. The consensus estimate of ~53% YoY decline for 2019 revenue, however, appears realistic as Moderna's top-line has been shrinking at ~53% YoY on average in the previous three quarters. Furthermore, the ~$83.8M of revenue forecasted for 2020 with a YoY growth of ~32% seems prudent ahead of more collaborations and the expected milestone payments from the current partners next year.
The higher costs associated with a public company have surged Moderna's LTM operating costs by ~32% from a year ago, while the operating loss as of Q3 2019 climbed to more than seven times the revenue. With more collaborations sharing the development cost and bringing additional revenue, the operating expenses and losses, however, could fall next year.
Source: koyfin.com
Despite the sharp decline in LTM revenue, the cash and cash equivalents as of Q3 2019 have only declined ~1% YoY. The company revised up the year-end liquidity level to ~$1.20B of cash and cash equivalents from ~$1.15B - ~$1.2B forecasted earlier, still a decline of ~21% YoY from the level in 2018. Having adjusted for the last year's IPO, where the net proceeds amounted to ~$563M, the forecast, however, indicates a growth of ~25% YoY, a robust expansion, given the clinical trials Moderna is advancing unassisted. The existing funding level at ~$1.5B as of Q3 2019 in cash and grants could sustain the operations for nearly three years at the current LTM cash burn rate, which could further improve in the event of more partnerships.
Source: koyfin.com
Moderna is not alone in mRNA-based therapeutics, but its expansive candidate pool capable of striking collaborations sets it apart from peers such as ProQR Therapeutics N.V. (PRQR) and Translate Bio, Inc. (TBIO). Both are clinical-stage biotech companies with a limited pool of drug candidates. Yet, Moderna currently trades at ~101.5x and ~77.0x in terms of its estimated 2019 and 2020 revenue, respectively, implying a ~15% and at ~54% of discount compared to the average peer multiples for the respective years.
Source: The Author; Data from Seeking Alpha
Focused on visual and auditory impairments, ProQR's drug pipeline targets only three indications. The latest timeline for the interim data is in Q1 2020 from its clinical candidate QR-421a for syndromic and non-syndromic retinitis pigmentosa (RP). The Phase 2/3 trial for Sepofarsen targeting LCA10 (Leber's Congenital Amaurosis 10) is ongoing with topline data expected in the first half of 2021. Despite an LTM revenue decline of ~42% YoY and a ~38% YoY decline in cash and equivalents, the company trades at ~131.4x and ~226.9x of its 2019 and 2020 revenue forecast, respectively. Despite having only one drug candidate, the price to forward sales multiples for Translate Bio currently stand at ~106.9x and ~105.5x for 2019 and 2020, respectively. Its MRT5005 is undergoing phase 1/2 clinical trial targeting cystic fibrosis as company focuses on pre-clinical research to treat a range of pulmonary diseases.
The ~15% discount based on the average peer multiple for 2019 highlights a compelling 'Buying' opportunity as the company expects a range of catalysts in the near term: phase 1 and 2 data readouts are pending for PCV, VEGF-A has a phase 2a readout, and CMV vaccine awaits the start of the phase 2 dose confirmation study. Moreover, the discount for 2020 price to forward sales multiple further reinforces the attractiveness of the stock with even the relatively lower price to sales multiple of Translate Bio, suggesting a discount of ~27%.
Targeting a range of diseases from viral infections to cardiac failure, Moderna's development program is extensive. With many promising candidates, the selectivity afforded by the disparate pool of drugs, however, gives it a higher bargaining power in partnership negotiations. The lack of focus can be a weakness too. Some clinical programs without a partner may be costly to develop, given the inadequate market opportunity, while the collaborations will force the company to share profits from lucrative candidates despite the costly initial development.
Therefore, Moderna could streamline its drug portfolio, offloading the less lucrative candidates through collaborations. An unhindered development of breakthrough therapies could be made possible by the resultant decline in research expenses and improved liquidity. The CMV vaccine, which has reached an advanced stage in development without a partner, can be such a highly valued candidate, given the vast market opportunity. The impending phase 2 and pivotal phase 3 trials could step up R&D costs for the vaccine, even though the company expects its pre-investment expenditure to only impact the 2020 bottom-line.
Despite shrinking revenue in recent quarters, Moderna's liquidity remains steady. A number of promising drug candidates with positive phase 1 data could attract more collaborations next year boosting revenue and cutting expenses. And yet, the company is trading at a sizable discount to its peers in terms of price to forward sales for both 2019 and 2020. Amid the impending catalysts from ongoing clinical trials, the undervalued stock implies a clear opportunity to 'Buy'. Meanwhile, more collaborations could refocus the clinical programs and sustain the rich premium the stock deserves.
If you enjoyed this article and wish to receive updates on my latest research, click "Follow" next to my name at the top.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Link:
Moderna: Undervalued As The Promising Pipeline Awaits Collaborations - Seeking Alpha
- Cardiac Regeneration - Center for Regenerative Medicine - Mayo Clinic ... - April 11th, 2018 [April 11th, 2018]
- Cardiac Regeneration - Mayo Clinic - April 22nd, 2018 [April 22nd, 2018]
- Materials - MDPI - May 18th, 2018 [May 18th, 2018]
- Cardiac Stem Cell Research - Cedars-Sinai - May 22nd, 2018 [May 22nd, 2018]
- Cardiac regeneration: current therapiesfuture concepts ... - May 26th, 2018 [May 26th, 2018]
- Cardiac Regeneration - Victor Chang Cardiac Research Institute - May 30th, 2018 [May 30th, 2018]
- Cardiology Conferences | Cardio 2018 Events | Cardiac ... - June 6th, 2018 [June 6th, 2018]
- Laboratory for Cardiac Regeneration | Baylor College of ... - June 18th, 2018 [June 18th, 2018]
- Regeneration of Muscle - July 8th, 2018 [July 8th, 2018]
- Regeneration of Muscle - eLS: Essential for Life Science - July 14th, 2018 [July 14th, 2018]
- Cardiac Repair and Regeneration Research Unit | Heart and ... - July 25th, 2018 [July 25th, 2018]
- Myogenesis - Wikipedia - August 8th, 2018 [August 8th, 2018]
- Regeneration (biology) - Wikipedia - August 21st, 2018 [August 21st, 2018]
- World Cardiology and Cardiologist Meeting - August 21st, 2018 [August 21st, 2018]
- Cardiac (comics) - Wikipedia - August 26th, 2018 [August 26th, 2018]
- Cardiac regeneration and repair - 1st Edition - Elsevier - September 21st, 2018 [September 21st, 2018]
- Post-doc position available cardiac regeneration ... - September 29th, 2018 [September 29th, 2018]
- UW Bioengineering: Building World Leadership in Heart ... - September 29th, 2018 [September 29th, 2018]
- Cardiac Regeneration - What Science Can Do - AstraZeneca - October 2nd, 2018 [October 2nd, 2018]
- Cardiac Regeneration, Stem Cells | Research | Baylor ... - November 30th, 2018 [November 30th, 2018]
- Cardiac Regeneration - Victor Chang Institute - December 6th, 2018 [December 6th, 2018]
- Entering a new era in vascular and cardiac regeneration ... - December 19th, 2018 [December 19th, 2018]
- Cardiac regeneration and repair - 1st Edition - December 19th, 2018 [December 19th, 2018]
- Heart Regeneration Technologies - December 19th, 2018 [December 19th, 2018]
- Cardiac Regeneration - Center for Regenerative Medicine ... - December 19th, 2018 [December 19th, 2018]
- Zebrafish Heart Regeneration | HHMI BioInteractive - December 22nd, 2018 [December 22nd, 2018]
- Rapid cell regeneration - Heroes Wiki - December 22nd, 2018 [December 22nd, 2018]
- Cardiac muscle - Wikipedia - December 23rd, 2018 [December 23rd, 2018]
- Cardiac regeneration in and : discrepancies and problems ... - January 8th, 2019 [January 8th, 2019]
- OHSU Center for Regenerative Medicine Heart Regeneration ... - January 8th, 2019 [January 8th, 2019]
- Dr. Sanjiv Dhingra, Cardiac Regeneration and Tissue ... - January 30th, 2019 [January 30th, 2019]
- Mending a Broken Heart: Stem Cells and Cardiac Repair ... - February 20th, 2019 [February 20th, 2019]
- Cardiac Repair and Regeneration | Division of Cardiology ... - February 20th, 2019 [February 20th, 2019]
- Stem Cell Therapy and Stem Cell Injection Provider Finder ... - March 5th, 2019 [March 5th, 2019]
- KearnsSayre syndrome - Wikipedia - March 8th, 2019 [March 8th, 2019]
- Ruohola-Baker Lab - March 15th, 2019 [March 15th, 2019]
- MTS Science - May 3rd, 2019 [May 3rd, 2019]
- New Insights Into the Healing Capacity of the Heart: The Hippo Pathway - Cath Lab Digest - September 26th, 2019 [September 26th, 2019]
- Conjugated polymers optically regulate the fate of endothelial colony-forming cells - Science Advances - September 29th, 2019 [September 29th, 2019]
- The nanoengineer working to mend broken hearts - UNSW Newsroom - September 29th, 2019 [September 29th, 2019]
- New insights into heart's healing capacity - Baylor College of Medicine News - September 29th, 2019 [September 29th, 2019]
- Tenaya Therapeutics Closes $92 Million Series B Financing - BioSpace - October 5th, 2019 [October 5th, 2019]
- Regenerative medicine today: Are diabetes and vascular disease treatments ready for the clinic? - Science Magazine - October 5th, 2019 [October 5th, 2019]
- Reviewing resTORbio Inc. (TORC)'s and Anika Therapeutics Inc. (NASDAQ:ANIK)'s results - MS Wkly - October 14th, 2019 [October 14th, 2019]
- TAMassociati: the new Church of the Resurrection in Varignano - Floornature.com - October 14th, 2019 [October 14th, 2019]
- What the Hippo pathway in cardiac fibroblasts reveals about heart function - Baylor College of Medicine News - October 19th, 2019 [October 19th, 2019]
- Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD) - BioSpace - October 22nd, 2019 [October 22nd, 2019]
- Regenerative Medicine Market Industry Outlook, Growth Prospects and Key Opportunities - Health News Office - October 24th, 2019 [October 24th, 2019]
- Ottawa-based treatment a leap forward in addressing heart failure - Winnipeg Sun - October 27th, 2019 [October 27th, 2019]
- Global Regenerative Medicines Market Demand Analysis & Opportunity Evaluation Report 2019-2027 with Focus on U.S. & Europe -... - November 15th, 2019 [November 15th, 2019]
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 15th, 2019 [November 15th, 2019]
- SANUWAVE Health Reports Third Quarter 2019 Financial Results Other OTC:SNWV - GlobeNewswire - November 16th, 2019 [November 16th, 2019]
- Comparative Study of the Therapeutic Potential of Mesenchymal Stem Cells Derived from Adipose Tissue and Bone Marrow on Acute Myocardial Infarction... - November 23rd, 2019 [November 23rd, 2019]
- Stem Cell Therapy May Improve Heart Health In New Ways - TheHealthMania - December 5th, 2019 [December 5th, 2019]
- AgeX Therapeutics Issues Year-End Letter to Shareholders - BioSpace - December 9th, 2019 [December 9th, 2019]
- Polymeric Biomaterials Market Trends Analysis Forecast to 2019-2024 |Evolving Industry Overview by Types, Applications, Size & Share - Sino News... - December 16th, 2019 [December 16th, 2019]
- SMD - Researchers look behind the biological curtain on how fish oil might fight inflammatory disease - QMUL - December 16th, 2019 [December 16th, 2019]
- Suspended animation, you say? The biggest and freakiest scientific breakthroughs of 2019 - SYFY WIRE - December 29th, 2019 [December 29th, 2019]
- 2019: Year in Pictures by Robert Cohen | Metro - STLtoday.com - December 31st, 2019 [December 31st, 2019]
- MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology... - January 15th, 2020 [January 15th, 2020]
- Cells that regenerate heart in zebrafish discovered - Biology Reporter - February 7th, 2020 [February 7th, 2020]
- SANUWAVE Health Appoints Dr. Tom Price to Its Board of Directors - Yahoo Finance - February 7th, 2020 [February 7th, 2020]
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - Associated Press - March 19th, 2020 [March 19th, 2020]
- Researchers and Doctors alike pursuing the field of stem cell research in treating heart attack survivors - Medical Herald - March 19th, 2020 [March 19th, 2020]
- Artificial Heart Lung Machines Market report reviews opportunities and analysis by size, share, trends, manufacturer, forecast 2020-2026 - WhaTech... - April 29th, 2020 [April 29th, 2020]
- Scientists have figured out how to make the heart to regenerate - The Times Hub - April 29th, 2020 [April 29th, 2020]
- Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat dietinduced obesity - Science Advances - May 9th, 2020 [May 9th, 2020]
- SANUWAVE HEALTH : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold First Quarter Financial Results and Business Update Call on Monday, May 18, 2020 - Yahoo Finance - May 15th, 2020 [May 15th, 2020]
- SANUWAVE Health to Hold Investor Live Webcast on Wednesday, June 10, 2020 - Yahoo Finance - June 10th, 2020 [June 10th, 2020]
- SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity's UltraMIST and Exclusive Partnership Rights for Wound Care Biologic... - June 11th, 2020 [June 11th, 2020]
- SANUWAVE Health, Inc. Discusses The Potential of Their Celularity Acquisition with The Stock Day Podcast (SNWV) July 1, 2020 - Stock Day Media - July 1st, 2020 [July 1st, 2020]
- Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented at the 2020 Congress of the European Society of Cardiology - PRNewswire - July 1st, 2020 [July 1st, 2020]
- Growth and demand of Plasma Therapy in the Asia Pacific Region available in the latest report - WhaTech Technology and Markets News - July 4th, 2020 [July 4th, 2020]
- Plasma Therapy Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line - August 14th, 2020 [August 14th, 2020]
- Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen for Vascular Repair - BioSpace - August 14th, 2020 [August 14th, 2020]
- Polymeric Biomaterials Market Insights by Current Trends 2020 Future Demand by Top Key Players, Regions, Industry Size, and Business Strategy... - September 11th, 2020 [September 11th, 2020]
- CORRECTION - SANUWAVE Health Announces Reimbursement Coverage for BIOVANCE From Largest Medicare and Medicaid Administrator in U.S. - Stockhouse - September 11th, 2020 [September 11th, 2020]
- New Research Paper Suggests RegeneRx's Thymosin Beta 4 May be Useful in Treating COVID-19 - PRNewswire - September 11th, 2020 [September 11th, 2020]
- To Repair a Damaged Heart, Three Cells are Better Than One - SDSU Newscenter - September 11th, 2020 [September 11th, 2020]